EG432995 Inhibitors
EG432995 inhibitors belong to a class of chemical compounds designed to specifically interact with and modulate the function of their target molecules, typically proteins or enzymes involved in cellular processes. The structure of these inhibitors often features a core scaffold that enables binding to a target protein's active or allosteric site, thereby affecting the protein's biological activity. The core structure of these inhibitors is generally composed of aromatic rings, heterocyclic systems, and functional groups that allow precise spatial orientation and binding affinity. The molecular interactions between EG432995 inhibitors and their targets include hydrogen bonding, hydrophobic contacts, and π-π stacking interactions, which confer specificity and potency to the inhibitors. These interactions are critical to their effectiveness in blocking or modifying the function of their target proteins. The inhibitors are designed to be highly selective to minimize off-target interactions and maximize their impact on their intended molecular pathway.
The chemical design of EG432995 inhibitors is tailored to achieve favorable pharmacokinetic and stability properties, ensuring the compounds remain stable under physiological conditions and effectively reach their targets within biological systems. Their solubility, bioavailability, and metabolic stability are optimized through chemical modifications such as the inclusion of polar functional groups or hydrophobic moieties, depending on the desired balance between solubility and membrane permeability. Additionally, the chemical structures of these inhibitors are modified to resist enzymatic degradation and improve their half-life, allowing for a sustained effect on their target molecules. Overall, the design principles behind EG432995 inhibitors emphasize both target specificity and favorable physicochemical properties to ensure their efficacy in modulating specific biological pathways without being prematurely degraded or inactivated.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
THL inhibits lipases, impacting lipid metabolism. Directly targeting lipid droplet formation, it may hinder Smim22's involvement in this process, potentially disrupting cellular lipid dynamics and inhibiting lipid droplet biogenesis. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 dihydrochloride monohydrate inhibits Rho-associated protein kinase (ROCK), influencing actin cytoskeleton organization. Indirectly, it may modulate Smim22's predicted role in the regulation of actin cytoskeleton, potentially affecting cellular morphology and migration. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A inhibits actin polymerization. Directly targeting actin dynamics, it may impede Smim22's involvement in the regulation of actin cytoskeleton organization, influencing cellular morphology and potentially inhibiting cell migration. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 inhibits neutral sphingomyelinase, impacting lipid metabolism. By modulating sphingolipid pathways, it indirectly influences Smim22's potential role in lipid droplet formation, potentially disrupting cellular lipid dynamics and inhibiting lipid droplet biogenesis. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin inhibits myosin II ATPase, affecting actin dynamics. Indirectly, it may modulate Smim22's predicted role in the regulation of actin cytoskeleton, potentially altering cellular morphology and inhibiting cell migration. | ||||||
GSK 269962 | 850664-21-0 | sc-363279 sc-363279A | 10 mg 50 mg | $300.00 $1000.00 | 1 | |
GSK 269962A inhibits ROCK1, impacting actin cytoskeleton organization. Indirectly, it may modulate Smim22's role in the regulation of actin dynamics, influencing cellular morphology and potentially inhibiting cell migration. | ||||||
Fatostatin | 125256-00-0 | sc-507496 | 100 mg | $450.00 | ||
Fatostatin inhibits SREBP, affecting lipid metabolism. Indirectly, it may modulate Smim22's potential involvement in lipid droplet formation, disrupting cellular lipid dynamics and inhibiting the biogenesis of lipid droplets. | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $321.00 $1040.00 | 5 | |
CK-666 inhibits the Arp2/3 complex, impacting actin polymerization. Directly targeting actin dynamics, it may interfere with Smim22's predicted role in the regulation of actin cytoskeleton, influencing cellular morphology and potentially inhibiting cell migration. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic Acid inhibits lipid metabolism enzymes. By modulating lipid metabolism, it may indirectly affect Smim22's potential involvement in lipid droplet formation, disrupting cellular lipid dynamics and inhibiting lipid droplet biogenesis. | ||||||